Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 15/20 | 0.38 |
| ▸ | RXRA | P19793 | 14/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 14/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29890232 | 1.00 | GRIN2B (0.38) | GRIN2BRXRAGRIN1MAOBKMT2A | |
| SCHEMBL7779435 | 0.83 | ESR1 (0.38) | KMT2AALDH1A1MAPT | |
| SCHEMBL27859538 | 0.82 | MAOB (0.41) | MAOBADRA2AADRA2BADRA2CLMNA | |
| SCHEMBL28043602 | 0.78 | GRIN2B (0.40) | GRIN2BRXRAGRIN1KMT2AALDH1A1 | |
| SCHEMBL363523 | 0.78 | HSD17B10 (0.46) | GRIN2BRXRAGRIN1KMT2AALDH1A1 | |
| SCHEMBL22431611 | 0.78 | MAOB (0.36) | MAOBALDH1A1MAPT | |
| SCHEMBL900869 | 0.75 | ALDH1A1 (0.45) | GRIN2BRXRAGRIN1KMT2AALDH1A1 | |
| SCHEMBL29525099 | 0.75 | GRIN2B (0.41) | GRIN2BRXRAGRIN1KMT2AALDH1A1 | |
| SCHEMBL30349361 | 0.75 | GRIN2B (0.41) | GRIN2BRXRAGRIN1KMT2AALDH1A1 | |
| SCHEMBL14386474 | 0.75 | GRIN2B (0.41) | GRIN2BRXRAGRIN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024220917-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
| CN-117062804-A | 1, 3-substituted cyclobutyl derivatives and their use | 诺华股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-3707133-B1 | BTK INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211974-A1 | HSD17B13 INHIBITORS AND USES THEREOF | INIPHARM, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-09-17 | — | — | US | disclosed |
| EP-3707133-A1 | BTK INHIBITOR COMPOUNDS | Eli Lilly and Company (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-111278818-A | BTK inhibitor compounds | 伊莱利利公司 | 2020-06-12 | — | — | CN | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388585-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT1, PRMT5, PRMT6 | GRIN2B 2638/4885RXRA 3263/4885GRIN1 1572/4885 |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | GRIN2B 334/4885RXRA 1139/4885GRIN1 489/4885 |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | GRIN2B 334/4885RXRA 1139/4885GRIN1 489/4885 |
| US-20240376110-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT9 | GRIN2B 3173/4885RXRA 3713/4885GRIN1 2676/4885 |
| US-20230150940-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B1, HSD17B3, HSD17B13 | GRIN2B 2382/4885RXRA 1177/4885GRIN1 2527/4885 |
| US-12448388-B2 | PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT9 | GRIN2B 3173/4885RXRA 3713/4885GRIN1 2676/4885 |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | GRIN2B 2516/4885RXRA 3713/4885GRIN1 2493/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GRIN2B 334/4885RXRA 1139/4885GRIN1 489/4885 |
| US-20200290997-A1 | BTK INHIBITOR COMPOUNDS | BTK, SYK, LCK | GRIN2B 3979/4885RXRA 4614/4885GRIN1 3737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.